Developments in Leukaemia Care video

Efficacy and safety of Besponsa (inotuzumab ozogamicin) in the INO-VATE Study

Speaker: Professor David Marks

Duration: 06:45

David Marks is Professor in Haematology and Stem Cell Transplantation and Director of the Bristol Bone Marrow Transplant (BMT) Unit. He additionally holds Honorary Senior Lectureship at the University of Bristol. He received his medical education at the University of Melbourne, Australia, and his clinical training at the Royal Melbourne Hospital, before undertaking positions in London, UK, and Philadelphia, US.  Professor Marks’s research and scientific papers focus on clinical aspects of stem cell transplantation, acute lymphoblastic leukaemia (ALL) and infection.  Since 2016, he has been Medical Director of IMPACT, the UK transplant trials platform. He is currently Transplant Coordinator and Deputy Chair of the National Cancer Research Institute ALL working group, Chair of the Adjudication Committee of BSBMT and a member of the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. He has authored numerous scientific papers and chaired the ALL education session at the American Society of Hematology meeting in 2010.

In this video, Professor Marks discusses targeted therapies and the INO-VATE study with particular reference to the following:

  • The data from the extended 3 year follow up from the INO-VATE study
  • Impact of allograft transplants on survival
  • Blast counts and resulting outcomes
  • Safety data
    • Vs Standard Care
    • How to manage adverse events
    • Risk factors and approaches on avoiding veno-occlusive disease



PP-INO-GBR-0268. May 2020